Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference

Albert, Matthieu; Benito, José M.; Bhagani, Sanjay; Boesecke, Christoph; Deterding, Katja; Dominguez, Stéphanie; Fisher, Martin; Fontanet, Arnaud; García, Diego; Gilson, Richard; Guiguet, Marguerite; Hoepelman, Andy I. M.; Horban, Andrzéj; Katlama, Christine; Mallolas, Josép; Page, Emma; Peters, Lars; Pozniak, Anton; Prins, Maria; Puoti, Massimo; Rauch, Andri; Rodger, Alison; Rockstroh, Juergen; Soriano, Vincent; Stephan, Christoph; Thibault, Vincent; Tural, Cristina; Valantin, Marc‐Antoine; Laar, Thijs van de; Meer, Jan van der; Vella, Stefano; Vogel, Martin; Wit, Stéphane De; Autran, Brigitte; Clotet, Bonaventura; Danta, Mark; Journiac, Maxime; Matthews, Gail; Meyer-Olson, Dirk; Nelson, Mark; Schmidt, Reinhold; Wedemeyer, Heiner

doi:10.1097/qad.0b013e328343443b

Cited by 122 publications

(45 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Counseling for safe sex to prevent HCV transmission and regular testing for sexually transmitted infections are crucial for successful long-term care of HIVinfected patients (33).…”

Section: Discussionmentioning

confidence: 99%

“…Other than regular, periodic testing, tests for anti-HCV and HCV RNA load should be provided to patients with unexplained abnormal liver functions or to those diagnosed with recent sexually transmitted infections. Early treatment may be considered for patients who still have detectable HCV RNA 12 weeks after the onset of symptoms or 12 weeks after a putative exposure (1,33).…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, in HIV/HCV-coinfected patients treated with pegylated IFN plus ribavirin, the overall SVR in those infected with HCV genotype 1 is only 17% to 50% (4,30,31,39). While more studies are needed to identify the optimal treatments for HIV-infected patients with acute HCV infection (33), the treatment responses seen with acute HCV infection in HIVinfected populations are promising, with an overall SVR of 46% to 95%, even in patients with genotype 1 or 4 infections (1,43).…”

mentioning

confidence: 95%

See 2 more Smart Citations

Recent Hepatitis C Virus Infections in HIV-Infected Patients in Taiwan: Incidence and Risk Factors

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Counseling for safe sex to prevent HCV transmission and regular testing for sexually transmitted infections are crucial for successful long-term care of HIVinfected patients (33).…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 95%

See 1 more Smart Citation

Recent Hepatitis C Virus Infections in HIV-Infected Patients in Taiwan: Incidence and Risk Factors

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Combination therapy with ribavirin improves viral kinetics compared to interferon monotherapy, and it is recommended for HIV-positive patients with a-HCV [25,26]. Given the aggressive course of c-HCV infection in HIV-positive patients and the high SVR in a-HCV, targeting a-HCV with P/R to prevent progression to c-HCV is a feasible option, especially in regions with limited access to DAA.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis

Zhang

Nguyen²,

Yee³

et al. 2015

Intervirology

View full text Add to dashboard Cite

Background/Aims: Of the 35 million human immunodeficiency virus (HIV)-positive patients worldwide, 10-40% are coinfected with chronic hepatitis C virus (HCV). Compared to HCV-monoinfected patients, those coinfected experience decreased spontaneous HCV clearance, accelerated liver fibrosis, and a decreased response to anti-HCV therapy. We conducted a meta-analysis to estimate the efficacy of treating acute HCV in HIV-positive patients with peginterferon and ribavirin combination therapy. Methods: Two authors independently searched MEDLINE and EMBASE (2014) for English articles, and reviewed bibliographies and abstracts from major liver and HIV conferences (2011-2013). Original studies featuring at least 10 treatment-naive, HIV-positive adults infected with acute HCV and treated with peginterferon and ribavirin were included. Analyses were calculated using a random-effects model. Heterogeneity was assessed using the Cochrane Q test (p < 0.05) and the I² statistic (>50%). Results: From 12 studies (450 patients), the pooled sustained virological response (SVR) was 71.4% (95% CI 64.7-77.4; Q statistic = 22.20, p = 0.023, I² = 50.44). The rapid virological response (RVR; 7 studies, 196 patients) was 47.4% (95% CI 40.6-54.7), and the early virological response (EVR; 9 studies, 283 patients) was 82.8% (95% CI 67.0-92.0). The probability of an SVR was 93.1% (95% CI 84.9-97.0) in those who obtained an RVR (6 studies, 82 patients) and 85.9% (95% CI 78.7-91.0) if an EVR (7 studies, 168 patients) was reached. Conclusion: Peginterferon with ribavirin is an effective option for treating acute HCV in HIV-positive patients, especially if they achieve an RVR or an EVR.

show abstract

“…The situation is different for the HIV patients who are under regular screen and storage of pre-diagnostic blood samples. Nevertheless, we should consider that some HIV patients unable to show such antibody response [14].…”

Section: The Problem Of Acute Hcv Infectionmentioning

confidence: 99%

Acute Hepatitis C Virus Infection and Directly Acting Anti-Hepatitis C Virus Drugs

Alhaddad¹,

Elsabaawy²,

Elshaarawy³

et al. 2017

J Gastrointest Dig Syst

View full text Add to dashboard Cite

The best of care of Acute hepatitis C (AHC) infections in the evolving era of all oral directly acting antiviral drugs (DDAs) needs revision. The inevitable chronic liver disease in 80% of AHC infections justifies the advent of DDAs that expectedly will guarantee high cure rates. Unlike interferons, the short and ultra-short all oral DDAs regimens had revolutionized treatment strategies with better adherence and fewer complications. However, the costly price of DAAs added to the average expertise is still contrarily active. Up-to-date, studies concerning DAAs treatment for AHC mono-infection are sparse; indeed this represents an unmet need in modern AHC management.

show abstract

Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference

Cited by 122 publications

References 65 publications

Recent Hepatitis C Virus Infections in HIV-Infected Patients in Taiwan: Incidence and Risk Factors

Recent Hepatitis C Virus Infections in HIV-Infected Patients in Taiwan: Incidence and Risk Factors

Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis

Acute Hepatitis C Virus Infection and Directly Acting Anti-Hepatitis C Virus Drugs

Contact Info

Product

Resources

About